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© 2016 Macmillan Publishers Limited.Resistance to therapies targeting the estrogen pathway
remains a challenge in the treatment of estrogen receptor-positive breast cancer. To address
this  challenge,  a  systems biology approach was  used.  A  library  of  small  interfering  RNAs
targeting an estrogen receptor (ER)-and aromatase-centered network identified 46 genes that
are dispensable in estrogen-dependent MCF7 cells, but are selectively required for the survival
of  estrogen-independent  MCF7-derived  cells  and  multiple  additional  estrogen-independent
breast cancer cell lines. Integration of this information identified a tumor suppressor gene TOB1
as a critical determinant of estrogen-independent ER-positive breast cell survival. Depletion of
TOB1 selectively promoted G1 phase arrest and sensitivity to AKT and mammalian target of
rapmycin (mTOR) inhibitors in estrogen-independent cells but not in estrogen-dependent cells.
Phosphoproteomic  profiles  from  reverse-phase  protein  array  analysis  supported  by  mRNA
profiling identified a significant  signaling network reprogramming by TOB1 that  differed in
estrogen-sensitive and estrogen-resistant cell lines. These data support a novel function for
TOB1 in mediating survival of estrogen-independent breast cancers. These studies also provide
evidence for combining TOB1 inhibition and AKT/mTOR inhibition as a therapeutic strategy, with
potential  translational  significance for  the management of  patients  with  ER-positive breast
cancers.
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